Also known as: Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets. Its platform uses machine learning and integrated data sets to discover RNA-modifying drug candidates across multiple disease areas.
Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
